<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en"><title>Writing (English) | Daiki Kumakura</title><link rel="self" type="application/atom+xml" href="https://daikikumakura.github.io/feed-en.xml"/><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing.html"/><id>https://daikikumakura.github.io/feed-en.xml</id><updated>2026-11-22T18:00:00+09:00</updated><author><name>Daiki Kumakura</name><uri>https://daikikumakura.github.io/</uri></author><entry><title>How far RNA changes reflect protein changes after perturbation: a check with surface proteins in the same cells</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/rna-protein-perturbation-en.html"/><id>https://daikikumakura.github.io/writing/rna-protein-perturbation-en.html</id><published>2026-11-22T18:00:00+09:00</published><updated>2026-11-22T18:00:00+09:00</updated><summary xml:lang="en">Public CRISPR knockout data with RNA and surface proteins measured in the same cells were recomputed. The noise-corrected correlation between RNA and protein changes was 0.42, and for some knocked-out genes the protein fell while the gene&#x27;s own mRNA barely changed.</summary></entry><entry><title>Recomputing daraxonrasib 300 mg target-inhibition predictions from FDA-published values</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/daraxonrasib-target-en.html"/><id>https://daikikumakura.github.io/writing/daraxonrasib-target-en.html</id><published>2026-11-22T13:00:00+09:00</published><updated>2026-11-22T13:00:00+09:00</updated><summary xml:lang="en">The applicant&#x27;s statement that 300 mg daraxonrasib gives at least 90% RAS-pathway inhibition in all patients is recomputed in 4,096 virtual patients using only the PopPK model and the preclinical target-inhibition concentration-response in the FDA review.</summary></entry><entry><title>When does the survival benefit of tarlatamab maintenance accumulate?</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/dellphi305-time-benefit-en.html"/><id>https://daikikumakura.github.io/writing/dellphi305-time-benefit-en.html</id><published>2026-11-22T09:00:00+09:00</published><updated>2026-11-22T09:00:00+09:00</updated><summary xml:lang="en">Public DeLLphi-305 survival curves are integrated over a common 12-month window to describe accumulated absolute survival and progression-free time.</summary></entry><entry><title>Daraxonrasib dose fractionation: opposing exposure metrics</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/daraxonrasib-dose-fractionation-en.html"/><id>https://daikikumakura.github.io/writing/daraxonrasib-dose-fractionation-en.html</id><published>2026-11-21T18:00:00+09:00</published><updated>2026-11-21T18:00:00+09:00</updated><summary xml:lang="en">Published daraxonrasib coefficients show opposing peak and minimum-concentration changes after fractionation, with conditional rather than validated safety projections.</summary></entry><entry><title>Omnii-1 phages reached a patient. What does that establish?</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/omnii-phage-translation-en.html"/><id>https://daikikumakura.github.io/writing/omnii-phage-translation-en.html</id><published>2026-11-21T13:00:00+09:00</published><updated>2026-11-21T13:00:00+09:00</updated><summary xml:lang="en">Candidate prioritization, in-vitro activity, infection-site exposure and clinical outcomes are different claims in the Omnii-1 phage report.</summary></entry><entry><title>Predicting intestinal T-cell engager responses across organoid donors</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/intestinal-tce-donor-prediction-en.html"/><id>https://daikikumakura.github.io/writing/intestinal-tce-donor-prediction-en.html</id><published>2026-11-21T09:00:00+09:00</published><updated>2026-11-21T09:00:00+09:00</updated><summary xml:lang="en">A donor-level reanalysis of public normal intestinal organoid data compares mean, tissue-region and CEA-area regressions using held-out donor prediction at a fixed TCE concentration.</summary></entry><entry><title>Can increasing TCE concentration compensate for impaired T-cell function?</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/tce-exhaustion-dose-ceiling-en.html"/><id>https://daikikumakura.github.io/writing/tce-exhaustion-dose-ceiling-en.html</id><published>2026-11-20T18:00:00+09:00</published><updated>2026-11-20T18:00:00+09:00</updated><summary xml:lang="en">Reanalysis of human TYRP1 TCE assay means distinguishes low response ceilings from unstable high-concentration extrapolation.</summary></entry><entry><title>Predicting week-12 ctDNA detection from a week-3 measurement</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/tebentafusp-early-ctdna-en.html"/><id>https://daikikumakura.github.io/writing/tebentafusp-early-ctdna-en.html</id><published>2026-11-20T13:00:00+09:00</published><updated>2026-11-20T13:00:00+09:00</updated><summary xml:lang="en">A participant-level reanalysis of public tebentafusp data compares baseline and early detection states for predicting recorded week-12 ctDNA detection in 54 complete cases.</summary></entry><entry><title>Combination perturbations: how much remains beyond additivity?</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/combo-perturbation-additivity-en.html"/><id>https://daikikumakura.github.io/writing/combo-perturbation-additivity-en.html</id><published>2026-11-20T09:00:00+09:00</published><updated>2026-11-20T09:00:00+09:00</updated><summary xml:lang="en">A K562 CRISPRa reanalysis estimates nonadditive expression components, distinguishing response scaling, sampling noise and model-evaluation headroom.</summary></entry><entry><title>AI drug discovery claims and their evidence chain</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/ai-drug-claim-chain-en.html"/><id>https://daikikumakura.github.io/writing/ai-drug-claim-chain-en.html</id><published>2026-11-19T18:00:00+09:00</published><updated>2026-11-19T18:00:00+09:00</updated><summary xml:lang="en">An audit traces phase 2 AI-drug claims to their sources, distinguishing small outcome samples, interim pipeline counts, completion from success, and arguments about bottlenecks.</summary></entry><entry><title>Can antigen-positive fractions predict residual antigen-negative cells after a TCE?</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/her2-bystander-residual-cells-en.html"/><id>https://daikikumakura.github.io/writing/her2-bystander-residual-cells-en.html</id><published>2026-11-19T13:00:00+09:00</published><updated>2026-11-19T13:00:00+09:00</updated><summary xml:lang="en">Testing a one-parameter model on held-out HER2-positive mixture fractions and separated tumoroids reveals limits of a fraction-only explanation.</summary></entry><entry><title>400 mg with a meal or 600 mg two hours apart: comparing taletrectinib dosing instructions with FDA&#x27;s public models</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/taletrectinib-food-en.html"/><id>https://daikikumakura.github.io/writing/taletrectinib-food-en.html</id><published>2026-11-19T09:00:00+09:00</published><updated>2026-11-19T09:00:00+09:00</updated><summary xml:lang="en">FDA taletrectinib models compare food and dose conditions, distinguishing lower exposure, relative hepatic-toxicity hazards, and unverified regular-meal effects.</summary></entry><entry><title>Matching RNA counts does not determine intracellular organization</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/subcellpert-spatial-response-en.html"/><id>https://daikikumakura.github.io/writing/subcellpert-spatial-response-en.html</id><published>2026-11-18T18:00:00+09:00</published><updated>2026-11-18T18:00:00+09:00</updated><summary xml:lang="en">A SubcellPert metric diagnostic uses real RNA coordinates to show spatial-shape differences after counts, centroids and covariance have been matched.</summary></entry><entry><title>What first place means in drug-discovery AI benchmarks</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/benchmark-ranking-claims-en.html"/><id>https://daikikumakura.github.io/writing/benchmark-ranking-claims-en.html</id><published>2026-11-18T13:00:00+09:00</published><updated>2026-11-18T13:00:00+09:00</updated><summary xml:lang="en">PXR, LifeSciBench and AIntibody show why ranks, uncertainty, baselines and evaluation independence support different claims about AI performance.</summary></entry><entry><title>Vopimetostat and daraxonrasib: what AUC matching leaves unknown</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/vopimetostat-daraxonrasib-exposure-en.html"/><id>https://daikikumakura.github.io/writing/vopimetostat-daraxonrasib-exposure-en.html</id><published>2026-11-18T09:00:00+09:00</published><updated>2026-11-18T09:00:00+09:00</updated><summary xml:lang="en">Public PK summaries and conditional simulations separate AUC matching from concentration profiles, clinical interactions and combination-dose optimization.</summary></entry><entry><title>What does step-up dosing optimise? Reading the elranatamab and epcoritamab exposure-response papers</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/stepup-design-reading-en.html"/><id>https://daikikumakura.github.io/writing/stepup-design-reading-en.html</id><published>2026-11-17T18:00:00+09:00</published><updated>2026-11-17T18:00:00+09:00</updated><summary xml:lang="en">Elranatamab and epcoritamab studies distinguish first-dose exposure from step count and prophylaxis, with nonrandomized evidence limiting causal attribution.</summary></entry><entry><title>How many CTCs are needed to classify DLL3 positivity?</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/dll3-ctc-count-precision-en.html"/><id>https://daikikumakura.github.io/writing/dll3-ctc-count-precision-en.html</id><published>2026-11-17T13:00:00+09:00</published><updated>2026-11-17T13:00:00+09:00</updated><summary xml:lang="en">Public tarlatamab CTC data distinguish normalized counts from unknown denominators and quantify conditional precision around a 25% positivity threshold.</summary></entry><entry><title>Comparing B7-H3 and SEZ6 as additional targets alongside DLL3</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/dll3-antigen-coverage-en.html"/><id>https://daikikumakura.github.io/writing/dll3-antigen-coverage-en.html</id><published>2026-11-17T09:00:00+09:00</published><updated>2026-11-17T09:00:00+09:00</updated><summary xml:lang="en">Reanalysis of public SCLC coexpression tables compares additional RNA coverage from B7-H3 and SEZ6 across samples and cohorts, with bootstrap uncertainty and no protein or efficacy inference.</summary></entry><entry><title>How to take the first step: comparing elranatamab step-up designs and CRS with public models</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/elranatamab-stepup-en.html"/><id>https://daikikumakura.github.io/writing/elranatamab-stepup-en.html</id><published>2026-11-16T18:00:00+09:00</published><updated>2026-11-16T18:00:00+09:00</updated><summary xml:lang="en">Published elranatamab PK and first-dose CRS models compare step-up hypotheses while separating recalibration, later-dose risk, and untested clinical benefit.</summary></entry><entry><title>AI agents in pharmacometrics: execution and validity</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/pmx-ai-agents-landscape-en.html"/><id>https://daikikumakura.github.io/writing/pmx-ai-agents-landscape-en.html</id><published>2026-11-16T13:00:00+09:00</published><updated>2026-11-16T13:00:00+09:00</updated><summary xml:lang="en">A review of LLM-agent papers, a tutorial and software distinguishes code execution, model convergence and scientific validity. No new experiments were performed.</summary></entry><entry><title>What an M2 macrophage label conceals</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/macrophage-program-selection-en.html"/><id>https://daikikumakura.github.io/writing/macrophage-program-selection-en.html</id><published>2026-11-16T09:00:00+09:00</published><updated>2026-11-16T09:00:00+09:00</updated><summary xml:lang="en">Two-donor single-cell RNA data reveal differences between M2a and M2c stimulation conditions that disappear under a shared M2 label.</summary></entry><entry><title>GEMS: selecting cellular contexts for GWAS variants</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/gems-cell-context-selection-en.html"/><id>https://daikikumakura.github.io/writing/gems-cell-context-selection-en.html</id><published>2026-11-15T18:00:00+09:00</published><updated>2026-11-15T18:00:00+09:00</updated><summary xml:lang="en">A GEMS denominator audit separates annotation concentration from candidate coverage and from validation of a cellular experimental system.</summary></entry><entry><title>Relacorilant intermittent timing around nab-paclitaxel infusion</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/relacorilant-paclitaxel-timing-en.html"/><id>https://daikikumakura.github.io/writing/relacorilant-paclitaxel-timing-en.html</id><published>2026-11-15T13:00:00+09:00</published><updated>2026-11-15T13:00:00+09:00</updated><summary xml:lang="en">Published paclitaxel PK and a relacorilant model separate drug interactions from parent-exposure timing, with explicit limits on clinical interpretation.</summary></entry><entry><title>Does a readable perturbation label imply a predictable cellular response?</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/perturbenergy-representation-en.html"/><id>https://daikikumakura.github.io/writing/perturbenergy-representation-en.html</id><published>2026-11-15T09:00:00+09:00</published><updated>2026-11-15T09:00:00+09:00</updated><summary xml:lang="en">PerturbEnergy label accuracy and expression prediction are compared using reported results and a one-dimensional counterexample with explicit transfer limits.</summary></entry><entry><title>How much of a cell’s signaling history can we reconstruct?</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/iris-signaling-history-en.html"/><id>https://daikikumakura.github.io/writing/iris-signaling-history-en.html</id><published>2026-11-14T18:00:00+09:00</published><updated>2026-11-14T18:00:00+09:00</updated><summary xml:lang="en">IRIS response classification and reconstructed signaling histories: a threshold analysis of 130,000 predictions and a review of experimental validation.</summary></entry><entry><title>Cancer cachexia episodes and the prediction clock</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/cachexia-episode-clock-en.html"/><id>https://daikikumakura.github.io/writing/cachexia-episode-clock-en.html</id><published>2026-11-14T13:00:00+09:00</published><updated>2026-11-14T13:00:00+09:00</updated><summary xml:lang="en">A cachexia episode-table audit, checked against the paper&#x27;s text and code, distinguishes retrospective interval starts, nadir, and end, and shows why its blood analyses and risk models do not test lead time.</summary></entry><entry><title>Reading an affinity-prediction R² of 0.43 against the measurement-noise ceiling</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/affinity-noise-ceiling-en.html"/><id>https://daikikumakura.github.io/writing/affinity-noise-ceiling-en.html</id><published>2026-11-14T09:00:00+09:00</published><updated>2026-11-14T09:00:00+09:00</updated><summary xml:lang="en">ChEMBL cross-document IC50 differences yield conditional R² ceiling scenarios, with duplicate handling, assay heterogeneity and calibration limitations.</summary></entry><entry><title>How to read a Spearman of 0.74 for human half-life: checking Iambic&#x27;s claim with public data and plain baselines</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/enchant-half-life-en.html"/><id>https://daikikumakura.github.io/writing/enchant-half-life-en.html</id><published>2026-11-13T18:00:00+09:00</published><updated>2026-11-13T18:00:00+09:00</updated><summary xml:lang="en">Public half-life data and simple baselines clarify Enchant comparison claims, test-set variation, five-molecule prior knowledge, and derived-clearance limits.</summary></entry><entry><title>siRNA selection: target knockdown and transcriptional changes</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/sirna-response-selection-en.html"/><id>https://daikikumakura.github.io/writing/sirna-response-selection-en.html</id><published>2026-11-13T13:00:00+09:00</published><updated>2026-11-13T13:00:00+09:00</updated><summary xml:lang="en">Approximate poster coordinates illustrate siRNA candidate tradeoffs, reading uncertainty and why changed-gene counts do not directly measure off-target effects.</summary></entry><entry><title>Trastuzumab rezetecan weight dosing across ADC and payload exposure</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/rezetecan-weight-policy-en.html"/><id>https://daikikumakura.github.io/writing/rezetecan-weight-policy-en.html</id><published>2026-11-13T09:00:00+09:00</published><updated>2026-11-13T09:00:00+09:00</updated><summary xml:lang="en">A public ADC/payload model separates weight effects, residual variability and covariate effects without selecting a clinical dose.</summary></entry><entry><title>How many Phase II readouts would it take to judge &#x27;AI drugs still succeed 40% of the time&#x27;?</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/ai-phase2-sample-size-en.html"/><id>https://daikikumakura.github.io/writing/ai-phase2-sample-size-en.html</id><published>2026-11-12T18:00:00+09:00</published><updated>2026-11-12T18:00:00+09:00</updated><summary xml:lang="en">Exact binomial calculations show the uncertainty in small AI-drug phase 2 samples and the sample sizes needed for superiority or equivalence claims.</summary></entry><entry><title>Does lower DNA repair gene expression imply greater PARP inhibitor sensitivity?</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/zz-first-repair-function-en.html"/><id>https://daikikumakura.github.io/writing/zz-first-repair-function-en.html</id><published>2026-11-12T13:00:00+09:00</published><updated>2026-11-12T13:00:00+09:00</updated><summary xml:lang="en">Paired ZZ-FIRST expression panels distinguish coordinated repair and cell-cycle changes from functional HRR deficiency and added PARP-inhibitor benefit.</summary></entry><entry><title>Designing the data for virtual cells: a synthetic allocation audit inspired by Biohub</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/biohub-data-design-en.html"/><id>https://daikikumakura.github.io/writing/biohub-data-design-en.html</id><published>2026-11-12T09:00:00+09:00</published><updated>2026-11-12T09:00:00+09:00</updated><summary xml:lang="en">Four synthetic allocations of 28,800 cells separate sampling depth, donors, condition coverage, imputation bias, and sample-preparation costs.</summary></entry><entry><title>How was the physiological cliff at menopause reconstructed from data?</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/menopause-time-deconvolution-en.html"/><id>https://daikikumakura.github.io/writing/menopause-time-deconvolution-en.html</id><published>2026-11-11T18:00:00+09:00</published><updated>2026-11-11T18:00:00+09:00</updated><summary xml:lang="en">A synthetic deconvolution example separates response width from FMP-age variation and examines the timing information supporting menopause reconstruction.</summary></entry><entry><title>Can osimertinib plasma exposure establish tumor target inhibition?</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/osimertinib-target-site-en.html"/><id>https://daikikumakura.github.io/writing/osimertinib-target-site-en.html</id><published>2026-11-11T13:00:00+09:00</published><updated>2026-11-11T13:00:00+09:00</updated><summary xml:lang="en">A public osimertinib PBPK model separates plasma exposure, total tumor drug, and reversible binding, with absorption and partitioning sensitivity checks.</summary></entry><entry><title>AI aptamer discovery: what were the molecules binding to?</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/aptamer-assay-feedback-en.html"/><id>https://daikikumakura.github.io/writing/aptamer-assay-feedback-en.html</id><published>2026-11-11T09:00:00+09:00</published><updated>2026-11-11T09:00:00+09:00</updated><summary xml:lang="en">An audit of Google’s aptamer report checks hit-rate denominators, bead correction and unresolved threshold inconsistencies.</summary></entry><entry><title>Inavolisib renal dosing: AUC, peaks and troughs</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/inavolisib-renal-dose-en.html"/><id>https://daikikumakura.github.io/writing/inavolisib-renal-dose-en.html</id><published>2026-11-10T18:00:00+09:00</published><updated>2026-11-10T18:00:00+09:00</updated><summary xml:lang="en">Published inavolisib PK separates renal dose adjustment, AUC matching and concentration shape without predicting clinical benefit.</summary></entry><entry><title>Can an AI agent do a PK/PD analysis? Re-running a warfarin analysis with a public skill library</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/agent-pkpd-skills-en.html"/><id>https://daikikumakura.github.io/writing/agent-pkpd-skills-en.html</id><published>2026-11-10T13:00:00+09:00</published><updated>2026-11-10T13:00:00+09:00</updated><summary xml:lang="en">Four AI-agent warfarin PK/PD analyses expose hidden implementation and refitting failures despite similar headline results.</summary></entry><entry><title>Can blood proteins read immune aging? From cell states to proxy measurements</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/immune-aging-protein-proxy-en.html"/><id>https://daikikumakura.github.io/writing/immune-aging-protein-proxy-en.html</id><published>2026-11-10T09:00:00+09:00</published><updated>2026-11-10T09:00:00+09:00</updated><summary xml:lang="en">Cell recovery and protein-proxy errors answer different questions. Two numerical examples examine an immune-aging study without claiming clinical validation.</summary></entry><entry><title>Can initial mercaptopurine records predict subsequent neutrophil counts?</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/6mp-anc-forecast-en.html"/><id>https://daikikumakura.github.io/writing/6mp-anc-forecast-en.html</id><published>2026-11-09T18:00:00+09:00</published><updated>2026-11-09T18:00:00+09:00</updated><summary xml:lang="en">Public dosing and ANC records test baseline updating against simple forecasts, without establishing dose-optimization benefit.</summary></entry><entry><title>How much power did the second dose arm cost? Reading the FURVENT topline results</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/furvent-dose-arm-en.html"/><id>https://daikikumakura.github.io/writing/furvent-dose-arm-en.html</id><published>2026-11-09T13:00:00+09:00</published><updated>2026-11-09T13:00:00+09:00</updated><summary xml:lang="en">An event-count and power audit of FURVENT separates the cost of a third dose arm from claims about why the trial failed.</summary></entry><entry><title>How should single-cell metabolic state inference be validated?</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/metabolic-state-validation-en.html"/><id>https://daikikumakura.github.io/writing/metabolic-state-validation-en.html</id><published>2026-11-09T09:00:00+09:00</published><updated>2026-11-09T09:00:00+09:00</updated><summary xml:lang="en">Metabolite abundance, flux and metabolic capacity require different validation when interpreting single-cell RNA-based estimates.</summary></entry><entry><title>Before evaluating cross-context perturbation prediction: know the reproducibility bound</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/perturbation-reproducibility-bound-en.html"/><id>https://daikikumakura.github.io/writing/perturbation-reproducibility-bound-en.html</id><published>2026-11-08T18:00:00+09:00</published><updated>2026-11-08T18:00:00+09:00</updated><summary xml:lang="en">Noise-corrected Perturb-seq correlations clarify what cross-context virtual-cell prediction scores can and cannot show.</summary></entry><entry><title>Which experiment enriches the desired cells? A LabCompass inverse-design diagnostic</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/labcompass-inverse-design-en.html"/><id>https://daikikumakura.github.io/writing/labcompass-inverse-design-en.html</id><published>2026-11-08T13:00:00+09:00</published><updated>2026-11-08T13:00:00+09:00</updated><summary xml:lang="en">Twelve LabCompass culture designs distinguish measured target-cell enrichment from uncertainty reduction after model updates.</summary></entry><entry><title>Telisotuzumab vedotin initial dosing with public PK and exposure-response models</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/telisotuzumab-dose-tradeoff-en.html"/><id>https://daikikumakura.github.io/writing/telisotuzumab-dose-tradeoff-en.html</id><published>2026-11-08T09:00:00+09:00</published><updated>2026-11-08T09:00:00+09:00</updated><summary xml:lang="en">A reproducible PK and exposure–response comparison of fixed and initial lower doses of telisotuzumab vedotin.</summary></entry><entry><title>How many of Carbon-A&#x27;s 566 million gene candidates are real?</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/carbon-a-candidates-en.html"/><id>https://daikikumakura.github.io/writing/carbon-a-candidates-en.html</id><published>2026-11-07T18:00:00+09:00</published><updated>2026-11-07T18:00:00+09:00</updated><summary xml:lang="en">An audit of the October 18 Carbon-A snapshot distinguishes assembly redundancy, confidence, RefSeq agreement and missing predictions.</summary></entry><entry><title>Proteome-guided degrader design: separating target degradation from mitochondrial effects</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/proteome-degrader-toxicity-en.html"/><id>https://daikikumakura.github.io/writing/proteome-degrader-toxicity-en.html</id><published>2026-11-07T13:00:00+09:00</published><updated>2026-11-07T13:00:00+09:00</updated><summary xml:lang="en">Public proteomics and respiratory-chain data reveal the gains and limits of redesigning an androgen-receptor degrader.</summary></entry><entry><title>Amivantamab IV/SC PK bridging: is matching AUC sufficient?</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/amivantamab-iv-sc-en.html"/><id>https://daikikumakura.github.io/writing/amivantamab-iv-sc-en.html</id><published>2026-11-07T09:00:00+09:00</published><updated>2026-11-07T09:00:00+09:00</updated><summary xml:lang="en">Conditional numerical simulations of the public EMA model distinguish systemic input, finite-window AUC and predose concentration. Reference profiles are contrasted with observed PALOMA-3 geometric mean ratios without claiming clinical noninferiority, population reproduction or individual switching predictions.</summary></entry><entry><title>Co-clump proximity versus cellular communication: auditing CCI-seq</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/cci-seq-proximity-evidence-en.html"/><id>https://daikikumakura.github.io/writing/cci-seq-proximity-evidence-en.html</id><published>2026-11-06T18:00:00+09:00</published><updated>2026-11-06T18:00:00+09:00</updated><summary xml:lang="en">Public mouse-kidney metadata reproduces heterotypic Frequency scores while separating co-clump counts, cell pairs and random-label enrichment. Rare-pair denominators, replicate structure and recovered clump sizes define what proximity evidence can support.</summary></entry><entry><title>Imlunestrant plasma exposure, tumor evidence and dosing intervals</title><link rel="alternate" type="text/html" href="https://daikikumakura.github.io/writing/imlunestrant-tumor-interval-en.html"/><id>https://daikikumakura.github.io/writing/imlunestrant-tumor-interval-en.html</id><published>2026-11-06T13:00:00+09:00</published><updated>2026-11-06T13:00:00+09:00</updated><summary xml:lang="en">Observed aggregate PK fitting and a public PopPK reconstruction compare equal-average schedules. Hypothetical delayed filters show why tumor enrichment alone does not identify interval-dependent target effects.</summary></entry></feed>
